Baricitinib in Patients with Refractory Rheumatoid Arthritis

被引：0
|
作者：
Lunzer, R. [1 ]
机构：
[1] Krankenhaus Barmherzigen Bruder Graz Eggenberg, Interne Abt, Bergstr 27, A-8020 Graz, Austria
来源：
JOURNAL FUR MINERALSTOFFWECHSEL & MUSKULOSKELETTALE ERKRANKUNGEN | 2016年 / 23卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：60 / 61
页数：2
相关论文
共 50 条
  • [31] EFFECTS OF BARICITINIB ON HAEMOGLOBIN AND RELATED LABORATORY PARAMETERS IN RHEUMATOID ARTHRITIS PATIENTS
    Kay, J.
    Harigai, M.
    Rancourt, J.
    Dickson, C.
    Isaka, Y.
    Chen, L.
    Carmack, T.
    Hyslop, D.
    Muram, D.
    Macias, W.
    Bradley, J.
    Keystone, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 513 - 514
  • [32] Evaluate the Dose Efficacy Response Relationship of Baricitinib in Patients with Rheumatoid Arthritis
    Zhang, Xin
    Chua, Laiyi
    Ernest, C. Steven, II
    Macias, William
    Rooney, Terence
    San Tham, Lai
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [33] Baricitinib: Early Vs. Delayed Start in Patients with Rheumatoid Arthritis
    Taylor, Peter C.
    Tanaka, Yoshiya
    Cardoso, Anabela
    Zhong, Jinglin
    Chen, Yun-Fei
    Workman, Jennifer Lynn
    del Carmen Morales, Liliana
    Schiff, Michael
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [34] Effects of Baseline Patient Characteristics on Baricitinib Efficacy in Patients with Rheumatoid Arthritis
    Kremer, Joel M.
    Genovese, Mark C.
    Muram, David
    Zhong, Jinglin
    Alam, Jahangir
    Schiff, Michael
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [35] SAFETY PROFILE OF BARICITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS
    Genovese, M.
    Smolen, J.
    Takeuchi, T.
    Hyslop, D.
    MacIas, W.
    Rooney, T.
    Chen, L.
    Dickson, C.
    Riddle, J.
    Cardillo, T.
    Winthrop, K.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 28 - 28
  • [36] Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat
    Ekin, Ali
    Misirci, Salim
    Gorunen, Ahmet
    Coskun, Belkis Nihan
    Yagiz, Burcu
    Dalkilic, Ediz
    Pehlivan, Yavuz
    MEDICAL PRINCIPLES AND PRACTICE, 2025, 34 (01) : 75 - 86
  • [37] Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
    Taylor, Peter C.
    Keystone, Edward C.
    van der Heijde, Desiree
    Weinblatt, Michael E.
    del Carmen Morales, Liliana
    Reyes Gonzaga, Jaime
    Yakushin, Sergey
    Ishii, Taeko
    Emoto, Kahaku
    Beattie, Scott
    Arora, Vipin
    Gaich, Carol
    Rooney, Terence
    Schlichting, Douglas
    Macias, William L.
    de Bono, Stephanie
    Tanaka, Yoshiya
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07): : 652 - 662
  • [38] Baricitinib exposure during pregnancy in rheumatoid arthritis
    Costanzo, Giulia
    Firinu, Davide
    Losa, Francesca
    Deidda, Margherita
    Barca, Maria P.
    Del Giacco, Stefano
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2020, 12
  • [39] BARISUR STUDY: DESCRIPTIVE STUDY OF BARICITINIB SAFETY IN SPANISH PATIENTS WITH RHEUMATOID ARTHRITIS
    Rubio Romero, E.
    Gallego, A.
    Llanes, M.
    Delgado Vidal, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 736 - 736
  • [40] AUTOANTIBODY PROFILING FOR RESPONSE TO BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND NO OR LIMITED EXPOSURE TO METHOTREXATE
    Gamboa, L. Martinez
    Bang, H.
    Issa, M.
    Zuckerman, S.
    Cardoso, A.
    Holzkaemper, T.
    De Leonardis, F.
    de la Torre, I.
    Tanaka, Y.
    Feist, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 276 - 277
12345